Open Payments

EYAL KEDAR

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine
Where
CANTON, NY
NPI
1457599532
Received
$43,956 in 79 records, 2019 to 2025 ($22,200 general, $21,755 research)
As principal investigator
$1,857,798 of research payments to others in 184 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment4$1,458
2024General payment11$4,942
2024Research payment8$12,908
2023General payment8$6,283
2022General payment6$3,763
2022Research payment1$20
2021General payment5$5,114
2021Research payment3$1,103
2020General payment2$30
2020Research payment3$6,982
2019General payment27$607
2019Research payment1$740

By company

CompanyRecordsAmountYears
GlaxoSmithKline, LLC.30$27,0582019–2025
Eli Lilly and Company10$13,6532019–2024
AstraZeneca UK Limited2$1,8752023–2024
Janssen Biotech, Inc.8$6242019–2025
AstraZeneca Pharmaceuticals LP4$2332024
ABBVIE INC.6$1872019
Novartis Pharmaceuticals Corporation2$1432023–2025
PFIZER INC.12$722019–2021
Boehringer Ingelheim Pharmaceuticals, Inc.1$412019
Amgen Inc.1$252019
E.R. Squibb & Sons, L.L.C.1$142019
Alexion Pharmaceuticals, Inc.1$132019
Genentech USA, Inc.1$102019

By nature of payment

NatureRecordsAmount
Research payment16$21,755
Compensation for services other than consulting, including serving as faculty or as a speaker at a v16$18,750
Consulting Fee1$1,860
Food and Beverage34$842
Education11$597
Travel and Lodging1$150

Records

DateCompanyAmountNatureFormProductStudyYear
2025-10-22Janssen Biotech, Inc.$77EducationIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-08-19GlaxoSmithKline, LLC.$650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2025
2025-07-31Novartis Pharmaceuticals Corporation$80Food and BeverageIn-kind items and services2025
2025-04-02GlaxoSmithKline, LLC.$650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2025
2024-12-04Janssen Biotech, Inc.$68EducationIn-kind items and servicesTREMFYA Drug, Immunology2024
2024-11-26Eli Lilly and Company$4,692Research paymentCash or cash equivalentTALTZ Drug, ImmunologyEFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A2024
2024-11-15AstraZeneca Pharmaceuticals LP$150Travel and LodgingCash or cash equivalent2024
2024-11-15AstraZeneca Pharmaceuticals LP$67Food and BeverageCash or cash equivalent2024
2024-10-18AstraZeneca UK Limited$15Food and BeverageIn-kind items and services2024
2024-09-18GlaxoSmithKline, LLC.$975Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2024
2024-08-21GlaxoSmithKline, LLC.$1,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNUCALA Biological, IMMUNOLOGY2024
2024-08-20GlaxoSmithKline, LLC.$237Research paymentCash or cash equivalentBENLYSTA Biological, IMMUNOLOGYA PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-08-16Eli Lilly and Company$114Research paymentIn-kind items and servicesEFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A2024
2024-07-09GlaxoSmithKline, LLC.$7,314Research paymentIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGYA PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-07-09GlaxoSmithKline, LLC.$357Research paymentIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGYA PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-07-09GlaxoSmithKline, LLC.$75Research paymentIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGYA PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-07-09GlaxoSmithKline, LLC.$59Research paymentIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGYA PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-07-09GlaxoSmithKline, LLC.$57Research paymentIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGYA PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-06-27Janssen Biotech, Inc.$74EducationIn-kind items and servicesTREMFYA Drug, Immunology2024
2024-05-10GlaxoSmithKline, LLC.$975Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNUCALA Biological, IMMUNOLOGY2024
2024-02-08AstraZeneca Pharmaceuticals LP$14Food and BeverageIn-kind items and servicesSAPHNELO Biological, Inflammation and Autoimmunity2024
2024-02-08AstraZeneca Pharmaceuticals LP$0Food and BeverageIn-kind items and servicesSAPHNELO Biological, Inflammation and Autoimmunity2024
2024-01-18GlaxoSmithKline, LLC.$1,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNUCALA Biological, IMMUNOLOGY2024
2023-10-04GlaxoSmithKline, LLC.$975Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNUCALA Biological, IMMUNOLOGY2023
2023-08-10Janssen Biotech, Inc.$79EducationIn-kind items and servicesTREMFYA Drug, Immunology2023
2023-07-21Novartis Pharmaceuticals Corporation$63Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2023
2023-06-21GlaxoSmithKline, LLC.$1,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2023
2023-05-16Janssen Biotech, Inc.$55EducationIn-kind items and servicesTREMFYA Drug, Immunology2023
2023-05-05GlaxoSmithKline, LLC.$1,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNUCALA Biological, IMMUNOLOGY2023
2023-04-25AstraZeneca UK Limited$1,860Consulting FeeCash or cash equivalent2023
2023-03-15GlaxoSmithKline, LLC.$650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2023
2022-12-23GlaxoSmithKline, LLC.$975Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2022
2022-10-07GlaxoSmithKline, LLC.$1,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2022
2022-09-15Janssen Biotech, Inc.$91EducationIn-kind items and servicesTREMFYA Drug, Immunology2022
2022-05-25Janssen Biotech, Inc.$89EducationIn-kind items and servicesTREMFYA Drug, Immunology2022
2022-04-08Eli Lilly and Company$20Research paymentIn-kind items and servicesA PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH2022
2022-03-29GlaxoSmithKline, LLC.$1,300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2022
2022-02-16GlaxoSmithKline, LLC.$7Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2022
2021-12-20GlaxoSmithKline, LLC.$1,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2021
2021-12-07GlaxoSmithKline, LLC.$1,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2021
2021-09-21GlaxoSmithKline, LLC.$9Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2021
2021-07-28PFIZER INC.$4Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2021
2021-07-21GlaxoSmithKline, LLC.$2,700Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENLYSTA Biological, IMMUNOLOGY2021
2021-01-11Eli Lilly and Company$826Research paymentIn-kind items and servicesA PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH2021
2021-01-11Eli Lilly and Company$260Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L2021
2021-01-11Eli Lilly and Company$17Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L2021
2020-12-08Eli Lilly and Company$681Research paymentIn-kind items and servicesA PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH2020
2020-09-08Eli Lilly and Company$826Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L2020
2020-01-28GlaxoSmithKline, LLC.$13Food and BeverageIn-kind items and servicesNUCALA Biological, RESPIRATORY2020
2020-01-23GlaxoSmithKline, LLC.$17Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2020
2020-01-09Eli Lilly and Company$5,474Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L2020
2019-11-11Boehringer Ingelheim Pharmaceuticals, Inc.$41Food and BeverageIn-kind items and servicesOFEV Drug, RESPIRATORY2019
2019-11-10ABBVIE INC.$16Food and BeverageIn-kind items and servicesRinvoq Biological, Immunology2019
2019-11-09Janssen Biotech, Inc.$86Food and BeverageIn-kind items and servicesSIMPONI ARIA Biological, Immunology2019
2019-11-08Eli Lilly and Company$740Research paymentIn-kind items and servicesA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L2019
2019-10-30PFIZER INC.$3Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-10-17GlaxoSmithKline, LLC.$120Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2019
2019-10-04Genentech USA, Inc.$10Food and BeverageIn-kind items and servicesRituxan Biological, BioOncology/Immunology2019
2019-09-10GlaxoSmithKline, LLC.$17Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2019
2019-09-05ABBVIE INC.$14EducationIn-kind items and servicesRinvoq Biological, Immunology2019
2019-09-05ABBVIE INC.$14EducationIn-kind items and servicesRinvoq Biological, Immunology2019
2019-09-05ABBVIE INC.$14EducationIn-kind items and servicesRinvoq Biological, Immunology2019
2019-09-05ABBVIE INC.$14EducationIn-kind items and servicesRinvoq Biological, Immunology2019
2019-09-05PFIZER INC.$3Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-07-25PFIZER INC.$9Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-07-25PFIZER INC.$1Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-06-26GlaxoSmithKline, LLC.$13Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2019
2019-05-30PFIZER INC.$2Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-05-16ABBVIE INC.$112Food and BeverageIn-kind items and servicesHumira Biological, Immunology2019
2019-05-07GlaxoSmithKline, LLC.$8Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2019
2019-03-22PFIZER INC.$5Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-03-08Alexion Pharmaceuticals, Inc.$13Food and BeverageIn-kind items and servicesStrensiq Drug, Endocrinology2019
2019-03-06PFIZER INC.$2Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-03-01Amgen Inc.$25Food and BeverageIn-kind items and servicesEnbrel Biological, Inflammation2019
2019-02-15PFIZER INC.$10Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-02-07PFIZER INC.$14Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-01-16PFIZER INC.$2Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019
2019-01-11E.R. Squibb & Sons, L.L.C.$14Food and BeverageCash or cash equivalentORENCIA Biological, Immunology2019
2019-01-04PFIZER INC.$11Food and BeverageIn-kind items and servicesXELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-04ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$5,400Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-11-17Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$1,485A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian2025
2025-11-05ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$10,179Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-10-07ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$43Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-10-02ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$314Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-09-11Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$4,937A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in pa2025
2025-07-02ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$4,432Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-06-10ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$500Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-06-05ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$14Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-06-03GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$500A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2025
2025-05-30UCB SAST LAWRENCE HEALTH SYSTEM$1,850A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME2025
2025-05-27ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$275Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-05-16AstraZeneca Pharmaceuticals LPSAINT LAWRENCE HEALTH SYSTEM$20,934A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an2025
2025-05-07ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$2,416Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-05-01ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$3,646Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-04-28GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$405A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU2025
2025-04-24ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$45Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-04-03ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$2,285Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2025
2025-03-19AstraZeneca UK LimitedSAINT LAWRENCE HEALTH SYSTEM$1,610A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneou2025
2025-03-07ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$4,519M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit2025
2025-02-25Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$3,525An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and2025
2025-02-25Eli Lilly and CompanyST LAWRENCE HEALTH SYSTEM INC$16,551EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A2025
2025-02-06ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$2,328M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit2025
2025-01-28Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$31,711A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in pa2025
2025-01-14Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$8,769A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian2025
2024-12-30ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$5,400Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2024
2024-12-16GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$810A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-12-05ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$9,110Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2024
2024-11-20GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$250A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU2024
2024-11-20GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$2,088A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU2024
2024-11-20GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$675A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU2024
2024-11-20GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$10,000A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU2024
2024-10-28UCB SAST LAWRENCE HEALTH SYSTEM$4,350A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2024
2024-10-03ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$50Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2024
2024-10-03UCB SAST LAWRENCE HEALTH SYSTEM$135A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME2024
2024-09-25Eli Lilly and CompanyST LAWRENCE HEALTH SYSTEM INC$1,935EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH A2024
2024-09-04ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$5,776Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2024
2024-08-27GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$675A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2024
2024-05-09ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$11,650Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate2024
2024-04-08Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$7,428A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in pa2024
2024-03-28UCB SASAINT LAWRENCE HEALTH SYSTEM$6,500A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2024
2024-02-27AstraZeneca Pharmaceuticals LPSAINT LAWRENCE HEALTH SYSTEM$2,841A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an2024
2024-02-09UCB SAST. LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS$567A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2024
2024-02-07Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$6,000A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab t2024
2024-01-24AstraZeneca UK LimitedSAINT LAWRENCE HEALTH SYSTEM$3,045A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneou2024
2024-01-12UCB SASAINT LAWRENCE HEALTH SYSTEM$920A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2024
2024-01-09Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$45,912A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian2024
2024-01-02Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$128,986An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and2024
2024-01-02UCB SASAINT LAWRENCE HEALTH SYSTEM$538A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME2024
2023-12-31ABBVIE INC.ST LAWRENCE HEALTH SYSTEM$73A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2023
2023-11-29GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$6,500A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2023
2023-11-29GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$1,923A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2023
2023-11-29GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$675A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2023
2023-11-29GlaxoSmithKline, LLC.ST LAWRENCE HEALTH SYSTEM INC$2,500A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR2023
2023-10-02UCB SASAINT LAWRENCE HEALTH SYSTEM$3,805A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2023
2023-10-02UCB SASAINT LAWRENCE HEALTH SYSTEM$10,969A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME2023
2023-09-06Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$38,827An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and2023
2023-08-25UCB SAST LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS$567A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2023
2023-07-17ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$919A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis2023
2023-06-14UCB SASAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY$5,689A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2023
2023-06-01UCB SASAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY$6,061A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME2023
2023-05-25Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$30,211A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian2023
2023-05-03ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$4,416A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2023
2023-03-30ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$198A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2023
2023-03-24UCB SASAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY$12,282A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME2023
2023-03-08AstraZeneca Pharmaceuticals LPSAINT LAWRENCE HEALTH SYSTEM$49,127A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an2023
2023-03-07ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$462A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2023
2023-02-25PFIZER INC.ST LAWRENCE HEALTH SYSTEM$598A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED MULTICENTER DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PR2023
2023-02-16UCB SASAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY$15,723A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2023
2023-02-02ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$198A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2023
2023-01-25AstraZeneca UK LimitedSAINT LAWRENCE HEALTH SYSTEM$2,015A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneou2023
2023-01-15Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$18A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab t2023
2023-01-15Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$1,084A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ian2023
2023-01-11UCB SAST LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS$14,648A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATME2023
2023-01-06Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$3,062A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab t2023
2023-01-05ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$66A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2023
2023-01-04Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$194,138An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and2023
2023-01-03Novartis Pharmaceuticals CorporationSAINT LAWRENCE HEALTH RHEUMATOLOGY$100,914An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and2023
2022-12-31ABBVIE INC.ST LAWRENCE HEALTH SYSTEM$440A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2022
2022-12-06ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$4,200A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2022
2022-11-03ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$275A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2022
2022-11-03ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$621A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2022
2022-09-23ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$66A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History o2022
2022-09-15Novartis Pharmaceuticals CorporationST LAWRENCE HEALTH SYSTEM CLINICAL RESEARCH$12,652A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, 3-ARM MULTICENTER PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF IAN2022
2022-09-05UCB SASAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY$22,885A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2022
2022-08-11ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$1,875Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi2022
2022-08-10ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$4,700Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi2022
2022-08-10ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$540Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi2022
2022-08-04F. Hoffmann-La Roche AGST LAWRENCE HEALTH SYSTEM INC$2,200TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS2022
2022-08-04F. Hoffmann-La Roche AGST LAWRENCE HEALTH SYSTEM INC$500TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS2022
2022-08-04F. Hoffmann-La Roche AGST LAWRENCE HEALTH SYSTEM INC$1,000TOCILIZUMAB THERAPY FOR COVID 19 PNEUMONIA IN HOSPITALIZED PATIENTS2022
2022-06-09ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$2,750A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PM2022
2022-06-01Novartis Pharmaceuticals CorporationST LAWRENCE HEALTH SYSTEM ATTN CLINICAL RESEARCH$132,060AN OPEN-LABEL, MULTI-CENTER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED SECUKINUMAB STUDY AND2022
2022-04-22ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$3,700A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History o2022
2022-04-20ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$590A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History o2022
2022-04-20ABBVIE INC.ST LAWRENCE HEALTH SYSTEM INC$14,300Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated Wi2022
2022-04-14UCB SASAINT LAWRENCE HEALTH SYSTEM CARDIOLOGY$28,390A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2022
2022-03-11Eli Lilly and CompanyST LAWRENCE HEALTH SYSTEM INC$15,205A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH2022
2022-03-08Eli Lilly and CompanyCOVANCE-DALLAS$20A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH2022
2022-02-28UCB SAST LAWRENCE HEALTH SYSTEM MEDICAL CAMPUS$291A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

St. Lawrence CountyCanton village

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Canton, NY, county St. Lawrence County, NY, state New York; placed by its city name.

MeasurePlace (city or town)
Canton, NY
County
St. Lawrence County, NY
State
New York
Population B010037,167107,22619,852,366
Population, 2020 census P17,155108,50520,201,249
Median age B0100221.939.339.8
Under 18 B010018.8%19.9%20.5%
65 and over B0100113.0%18.8%17.9%
Households B110012,02941,6667,722,646
Foreign born B050026.0%3.7%22.8%
Median household income B19013$62,054$62,850$85,974
Median family income B19113$125,163$80,443$106,873
Per capita income B19301$24,044$33,177$50,712
Poverty rate B1700119.8%16.9%14.0%
Unemployment rate B230256.5%5.3%6.4%
Civilian labor force B230253,09447,29310,171,766
Mean commute (minutes) B0801313.121.032.6
Bachelor's degree or higher B1500353.9%25.3%40.2%
Housing units B250012,15351,9708,585,241
Owner-occupied B2500346.2%71.9%54.3%
Renters B2500353.8%28.1%45.7%
Median home value B25077$183,800$121,900$423,800
Median gross rent B25064$796$818$1,621
White, not Hispanic B0300283.9%91.2%52.8%
Black B030025.6%1.9%13.4%
Hispanic or Latino B030024.5%2.5%19.8%
Asian B030022.3%1.1%9.0%
American Indian and Alaska Native B030020.2%0.4%0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Canton, NY.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.